


UCLA Jonsson Comprehensive Cancer Center NEWSLETTER



UCLA researchers' discovery marks milestone in understanding treatment-resistant melanoma

Mutation-targeted therapies are turning the tide against metastatic melanoma, and new research by JCCC scientist Dr. Roger Lo is shedding important new light on how the disease evolves to become more resistant to these treatments. Findings of the three-year study, Lo said, could lead to new methods to enable early detection of drug-resistant tumor cells and improved therapies designed to suppress resistance as soon as therapy begins. [Read more >](#)

JCCC Member Resources

- Visit our [membership info page](#) to find out all of the benefits and privileges that are available to you as a JCCC member.

Clinical Trials at Your Fingertips

- Connect you and your patients with clinical trials at UCLA. [Click here](#) to learn all about how you can use any mobile device (including your smartphone) to access JCCC's clinical trials database.

Shared Resources at UCLA

- As a member you have access to several shared resources at JCCC, and over 70 additional shared resources at UCLA. Visit the [Shared Resources page](#) to learn more.

Funding Opportunities

- Members can now [access online](#) a complete list of the latest research grant opportunities directly from the JCCC website.

Update Your Member Profile

- Do you need a new member photo? Have new publications? Want to update your bio? Read the [member profile guidelines](#) to learn how.

Latest News

Is genetic testing of all women for breast cancer worth the cost?



Life threatening mutations in the BRCA-1 and BRCA-2 genes are usually found in families with a known history of breast and ovarian cancers, but the value of screening for these mutations remains doubtful due to the high cost of genetic testing. In a landmark multi-year study, JCCC member Dr. Patricia Ganz and assistant professor Dr. Elisa Long compared BRCA genetic testing to other diagnostic methods and found that it not as efficient and does not eliminate the need for yearly mammograms.

[Read more >](#)

Show you care



Did you know? The Jonsson Cancer Center Foundation offers a convenient way to honor a loved one, patient or colleague with a gift to support JCCC research. [Give any amount](#) you wish and then select an e-card image to send with your message. You can [make your gift now](#) and schedule your e-card to be sent automatically on a day of your choosing. It's easy, thoughtful and meaningful. For questions, please contact [Francesca Cota](#). Thank you for all the ways you advance cancer research.

UCLA researchers create a promising new treatment for the deadliest form of brain cancer



UCLA scientists Drs. Robert Prins and Linda Liaw have developed a potentially promising new combination therapy for glioblastoma. In the research, they used engineered adoptive T cell transfer to extract and grow immune cells outside of the body, then reprogrammed them with the gene for a T cell receptor targeting New York esophageal squamous carcinoma, or NY-ESO-1. The study found the method was about 50 percent effective at curing the disease.

[Read more >](#)

Social Networking Tools

- JCCC is on Twitter, Facebook and YouTube. Learn how to follow us and stay connected!



UCLA scientist develops experimental therapy to treat colon cancer and chronic inflammatory bowel disease



Utilizing a chemical inhibitor to block an RNA molecule (microRNA-214) involved in the transmission of genetic information, a team led by JCCC researcher Dr. Dimitrios Iliopoulos has discovered an experimental therapy with the ability to suppress the development of ulcerative colitis. The two-year study evaluated the drug in mice with ulcerative colitis and colon tumors and found that in both cases it was highly effective to suppress the disease.

[Read more >](#)

© 2014 UCLA Jonsson Comprehensive Cancer Center. All Rights Reserved.
[Terms & Conditions](#) | [Privacy Practices](#) | [About the JCCC Website](#)

Have feedback on this newsletter? Direct your questions and comments to: newsletter@mednet.ucla.edu